肺癌靶向治疗药物的心血管毒性  

Cardiovascular toxicity of targeted therapy in patients with lung cancer

作　　者：安涛(综述)[1] 韩森(审校)[2] Tao An;Sen Han(State Key Laboratory of Cardiovascular Disease,Fuwai Hospital,National Center for Cardiovascular Diseases,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]中国医学科学院北京协和医学院,国家心血管病中心,阜外医院心力衰竭中心,北京市100037 [2]北京大学肿瘤医院暨北京市肿瘤防治研究所,恶性肿瘤发病机制及转化研究教育部重点实验室

出　　处：《中国肿瘤临床》2021年第6期311-316,共6页Chinese Journal of Clinical Oncology

基　　金：北京大学肿瘤医院科学研究基金(编号:2020⁃自主⁃27)资助。

摘　　要：肺癌靶向治疗相关的心血管毒性并不少见。心律失常可能是肺癌靶向治疗中最突出的心血管毒性,其中以QT间期延长的危害最大。在接受奥希替尼和间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)抑制剂治疗的患者中,需特别警惕QT间期延长。高血压是抗血管内皮生长因子(vascular endothelial growth factor,VEGF)治疗和第三代ALK抑制剂中需关注的心血管毒性。针对HER-2靶向药物的心血管毒性相对较小。在接受MET抑制剂和ROS-1抑制剂患者中周围性水肿的发生率较高。临床治疗时需提高警惕,注意监测和处理靶向治疗中的各种心血管并发症。Cardiovascular toxicity associated with targeted therapy for lung cancer is not rare.Arrhythmias may be the most prominent cardiovascular toxicities,among which prolonged QT interval is the most harmful.In patients treated with osimertinib and anaplastic lymphoma kinase(ALK)inhibitors,special attention should be paid to the adverse effects of prolonged QT interval.Hypertension is a cardiovascular toxicity that should be considered in patients receiving anti-VEGF treatment and third-generation ALK inhibitors.The cardiotoxicity of HER-2-targeted drugs is not serious.The incidence of peripheral edema is high in patients receiving MET and ROS-1 inhibitors.Thus,oncologists should pay more attention to monitoring and managing cardiovascular complications in patients receiving targeted therapy.

关 键 词：肺癌 靶向治疗 心血管病 肿瘤心脏病学 

分 类 号：R734.2[医药卫生—肿瘤]